Medpace Holdings, Inc. Operating Cash Flow
Medpace Holdings, Inc. (MEDP) reported Operating Cash Flow of $313.80 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-07-23
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $162.01M, a 9.08% increase year-over-year.
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $151.79M, a 20.62% increase year-over-year.
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $192.65M, a 1.04% increase year-over-year.
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $246.21M, a 65.16% increase year-over-year.
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2025 was $713.22M, a 17.15% increase from fiscal 2024.
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $608.82M, a 40.48% increase from fiscal 2023.
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2023 was $433.37M, a 11.68% increase from fiscal 2022.
- Medpace Holdings, Inc. net cash provided by (used in) operating activities for fiscal 2022 was $388.05M, a 47.36% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $162.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $313.80M 10-Q · filed 2026-07-23 | $506.45M derived: sum of 3 quarters · filed 2026-07-23 | $752.66M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $151.79M 10-Q · filed 2026-04-23 | $344.44M derived: sum of 2 quarters · filed 2026-04-23 | $590.65M derived: sum of 3 quarters · filed 2026-04-23 | $739.17M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $192.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $438.86M derived: sum of 2 quarters · filed 2026-02-10 | $587.39M derived: sum of 3 quarters · filed 2026-07-23 | $713.22M 10-K · filed 2026-02-10 |
| 2025-09-30 | $246.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $394.74M derived: sum of 2 quarters · filed 2026-07-23 | $520.57M 10-Q · filed 2025-10-23 | $711.24M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $148.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $274.36M 10-Q · filed 2026-07-23 | $465.03M derived: sum of 3 quarters · filed 2026-07-23 | $614.10M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $125.84M 10-Q · filed 2026-04-23 | $316.50M derived: sum of 2 quarters · filed 2026-04-23 | $465.58M derived: sum of 3 quarters · filed 2026-04-23 | $581.97M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $190.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $339.74M derived: sum of 2 quarters · filed 2026-02-10 | $456.14M derived: sum of 3 quarters · filed 2026-02-10 | $608.82M 10-K · filed 2026-02-10 |
| 2024-09-30 | $149.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-23 | $265.47M derived: sum of 2 quarters · filed 2025-10-23 | $418.15M 10-Q · filed 2025-10-23 | $574.54M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $116.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-22 | $269.07M 10-Q · filed 2025-07-22 | $425.47M derived: sum of 3 quarters · filed 2026-02-10 | $539.85M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $152.68M 10-Q · filed 2025-04-22 | $309.07M derived: sum of 2 quarters · filed 2026-02-10 | $423.46M derived: sum of 3 quarters · filed 2026-02-10 | $505.98M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $156.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $270.78M derived: sum of 2 quarters · filed 2026-02-10 | $353.30M derived: sum of 3 quarters · filed 2026-02-10 | $433.37M 10-K · filed 2026-02-10 |
| 2023-09-30 | $114.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-22 | $196.90M derived: sum of 2 quarters · filed 2024-10-22 | $276.98M 10-Q · filed 2024-10-22 | $413.66M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $82.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-23 | $162.59M 10-Q · filed 2024-07-23 | $299.28M derived: sum of 3 quarters · filed 2025-02-11 | $407.77M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $80.08M 10-Q · filed 2024-04-23 | $216.76M derived: sum of 2 quarters · filed 2025-02-11 | $325.25M derived: sum of 3 quarters · filed 2025-02-11 | $421.87M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $136.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $245.18M derived: sum of 2 quarters · filed 2025-02-11 | $341.79M derived: sum of 3 quarters · filed 2025-02-11 | $388.05M 10-K · filed 2025-02-11 |
| 2022-09-30 | $108.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-24 | $205.11M derived: sum of 2 quarters · filed 2023-10-24 | $251.37M 10-Q · filed 2023-10-24 | $322.26M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $96.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $142.88M 10-Q · filed 2023-07-25 | $213.77M derived: sum of 3 quarters · filed 2024-02-13 | $286.12M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $46.26M 10-Q · filed 2023-04-25 | $117.15M derived: sum of 2 quarters · filed 2024-02-13 | $189.50M derived: sum of 3 quarters · filed 2024-02-13 | $252.26M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $70.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $143.25M derived: sum of 2 quarters · filed 2024-02-13 | $206.01M derived: sum of 3 quarters · filed 2024-02-13 | $263.33M 10-K · filed 2024-02-13 |
| 2021-09-30 | $72.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $135.11M derived: sum of 2 quarters · filed 2022-10-25 | $192.43M 10-Q · filed 2022-10-25 | $297.93M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $62.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-26 | $120.08M 10-Q · filed 2022-07-26 | $225.58M derived: sum of 3 quarters · filed 2023-02-14 | $285.34M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $57.32M 10-Q · filed 2022-04-26 | $162.82M derived: sum of 2 quarters · filed 2023-02-14 | $222.58M derived: sum of 3 quarters · filed 2023-02-14 | $266.85M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $105.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $165.26M derived: sum of 2 quarters · filed 2023-02-14 | $209.53M derived: sum of 3 quarters · filed 2023-02-14 | $258.68M 10-K · filed 2023-02-14 |
| 2020-09-30 | $59.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-26 | $104.03M derived: sum of 2 quarters · filed 2021-10-26 | $153.18M 10-Q · filed 2021-10-26 | $210.12M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $44.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27 | $93.42M 10-Q · filed 2021-07-27 | $150.35M derived: sum of 3 quarters · filed 2022-02-15 | $214.65M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $49.15M 10-Q · filed 2021-04-27 | $106.09M derived: sum of 2 quarters · filed 2022-02-15 | $170.38M derived: sum of 3 quarters · filed 2022-02-15 | $217.01M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $56.94M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $121.23M derived: sum of 2 quarters · filed 2022-02-15 | $167.86M derived: sum of 3 quarters · filed 2022-02-15 | $201.87M 10-K · filed 2022-02-15 |
| 2019-09-30 | $64.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-27 | $110.92M derived: sum of 2 quarters · filed 2020-10-27 | $144.93M 10-Q · filed 2020-10-27 | $184.37M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $46.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | $80.64M 10-Q · filed 2020-07-28 | $120.08M derived: sum of 3 quarters · filed 2021-02-16 | $172.58M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $34.01M 10-Q · filed 2020-04-29 | $73.45M derived: sum of 2 quarters · filed 2021-02-16 | $125.95M derived: sum of 3 quarters · filed 2021-02-16 | $167.29M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $39.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $91.94M derived: sum of 2 quarters · filed 2021-02-16 | $133.29M derived: sum of 3 quarters · filed 2021-02-16 | $156.58M 10-K · filed 2021-02-16 |
| 2018-09-30 | $52.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $93.84M derived: sum of 2 quarters · filed 2019-10-29 | $117.14M 10-Q · filed 2019-10-29 | $145.79M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $41.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-30 | $64.64M 10-Q · filed 2019-07-30 | $93.29M derived: sum of 3 quarters · filed 2020-02-25 | $132.29M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $23.30M 10-Q · filed 2019-04-30 | $51.95M derived: sum of 2 quarters · filed 2020-02-25 | $90.95M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2017-12-31 | $28.65M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $67.65M derived: sum of 2 quarters · filed 2020-02-25 | $97.39M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $39.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $68.73M 10-Q · filed 2018-10-30 | ||
| 2017-06-30 | $29.73M 10-Q · filed 2018-07-31 | |||
| 2016-12-31 | $91.73M 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |